All In Biotech

Drug Trial Radar · NCT06995001

Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Apr 28, 2024

Primary completion

Nov 28, 2024

Study completion Nov 28, 2024

Sponsor

Sponsor type
Industry
First posted
May 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics and immunogenicity of a single dose of SHR-2173 by subcutaneous injection.

Conditions

  • Healthy Volunteers

Interventions

  • SHR-2173Drug

    SHR-2173 injection dose 1;

  • SHR-2173 ;PlaceboDrug

    SHR-2173 injection dose 2 ;Pacebo dose 2

  • SHR-2173 ;PlaceboDrug

    SHR-2173 injection dose 3 ;Pacebo dose 3

  • SHR-2173 ;PlaceboDrug

    SHR-2173 injection dose 4 ;Pacebo dose 4

  • SHR-2173 ;PlaceboDrug

    SHR-2173 injection dose 5 ;Pacebo dose 5

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent Adverse Events (TEAE)Time frame: Day1~Day71

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Haikou People's Hospital

    Haikou, Hainan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.